Madhusmita Misra1, Neville H Golden2, Debra K Katzman3. 1. Division of Pediatric Endocrinology and the Neuroendocrine Unit, Massachusetts General Hospital, Boston, Massachusetts. 2. Division of Adolescent Medicine, Stanford University School of Medicine, Palo Alto, California. 3. Division of Adolescent Medicine, Hospital for Sick Children and University of Toronto, Toronto, Canada.
Abstract
OBJECTIVE: Low bone mineral density (BMD) is a known consequence of anorexia nervosa (AN) and is particularly concerning during adolescence, a critical time for bone accrual. A comprehensive synthesis of available data regarding impaired bone health, its determinants, and associated management strategies in AN is currently lacking. This systematic review aims to synthesize information from key physiologic and prospective studies and trials, and provide a thorough understanding of impaired bone health in AN and its management. METHOD: Search terms included "anorexia nervosa" AND "bone density" for the period 1995-2015, limited to articles in English. Papers were screened manually based on journal impact factor, sample size, age of participants, and inclusion of a control group. When necessary, we included seminal papers published before 1995. RESULTS: AN leads to low BMD, impaired bone quality and increased fracture risk. Important determinants are low lean mass, hypogonadism, IGF-1 deficiency, and alterations in other hormones that impact bone health. Weight gain and menses restoration are critical for improving bone outcomes in AN. Physiologic estrogen replacement as the transdermal patch was shown to increase bone accrual in one study in adolescent females with AN; however, residual deficits persist. Bisphosphonates are potentially useful in adults with AN. DISCUSSION: To date, evidence suggests that the safest and most effective strategy to improve bone health in AN is normalization of weight with restoration of menses. Pharmacotherapies that show promise include physiologic estradiol replacement (as the transdermal estradiol patch), and in adults, bisphosphonates. Further studies are necessary to determine the best strategies to normalize BMD in AN.
OBJECTIVE: Low bone mineral density (BMD) is a known consequence of anorexia nervosa (AN) and is particularly concerning during adolescence, a critical time for bone accrual. A comprehensive synthesis of available data regarding impaired bone health, its determinants, and associated management strategies in AN is currently lacking. This systematic review aims to synthesize information from key physiologic and prospective studies and trials, and provide a thorough understanding of impaired bone health in AN and its management. METHOD: Search terms included "anorexia nervosa" AND "bone density" for the period 1995-2015, limited to articles in English. Papers were screened manually based on journal impact factor, sample size, age of participants, and inclusion of a control group. When necessary, we included seminal papers published before 1995. RESULTS: AN leads to low BMD, impaired bone quality and increased fracture risk. Important determinants are low lean mass, hypogonadism, IGF-1 deficiency, and alterations in other hormones that impact bone health. Weight gain and menses restoration are critical for improving bone outcomes in AN. Physiologic estrogen replacement as the transdermal patch was shown to increase bone accrual in one study in adolescent females with AN; however, residual deficits persist. Bisphosphonates are potentially useful in adults with AN. DISCUSSION: To date, evidence suggests that the safest and most effective strategy to improve bone health in AN is normalization of weight with restoration of menses. Pharmacotherapies that show promise include physiologic estradiol replacement (as the transdermal estradiol patch), and in adults, bisphosphonates. Further studies are necessary to determine the best strategies to normalize BMD in AN.
Authors: S Grinspoon; E Thomas; S Pitts; E Gross; D Mickley; K Miller; D Herzog; A Klibanski Journal: Ann Intern Med Date: 2000-11-21 Impact factor: 25.391
Authors: John A Shepherd; Li Wang; Bo Fan; Vicente Gilsanz; Heide J Kalkwarf; Joan Lappe; Ying Lu; Thomas Hangartner; Babette S Zemel; Margaret Fredrick; Sharon Oberfield; Karen K Winer Journal: J Bone Miner Res Date: 2011-11 Impact factor: 6.741
Authors: Amy D Divasta; Henry A Feldman; Courtney Giancaterino; Clifford J Rosen; Meryl S Leboff; Catherine M Gordon Journal: Metabolism Date: 2012-01-16 Impact factor: 8.694
Authors: Maria Luisa Bianchi; Mary B Leonard; Susanne Bechtold; Wolfgang Högler; M Zulf Mughal; Eckhart Schönau; Francisco A Sylvester; Maria Vogiatzi; Marry M van den Heuvel-Eibrink; Leanne Ward Journal: J Clin Densitom Date: 2014-03-19 Impact factor: 2.617
Authors: Joanna Oświecimska; Katarzyna Ziora; Wojciech Pluskiewicz; Gabriela Geisler; Katarzyna Broll-Waśka; Dariusz Karasek; Antoni Dyduch Journal: Bone Date: 2007-04-06 Impact factor: 4.398
Authors: Pouneh K Fazeli; Miriam A Bredella; Madhusmita Misra; Erinne Meenaghan; Clifford J Rosen; David R Clemmons; Anne Breggia; Karen K Miller; Anne Klibanski Journal: J Clin Endocrinol Metab Date: 2009-10-22 Impact factor: 5.958
Authors: M T Muñoz-Calvo; V Barrios; M T García de Alvaro; M Lefort; C Méndez-Dávila; J Argente; C de la Piedra Journal: Scand J Clin Lab Invest Date: 2007 Impact factor: 1.713
Authors: Sridhar Vajapeyam; Kirsten Ecklund; Robert V Mulkern; Henry A Feldman; Jennifer M O'Donnell; Amy D DiVasta; Clifford J Rosen; Catherine M Gordon Journal: Bone Date: 2018-02-26 Impact factor: 4.398
Authors: Jason M Nagata; Neville H Golden; Mary B Leonard; Lawrence Copelovitch; Michelle R Denburg Journal: J Bone Miner Res Date: 2017-01-19 Impact factor: 6.741
Authors: Jason M Nagata; Anna Grandis; Paola Bojorquez-Ramirez; Anthony Nguyen; Amanda E Downey; Kyle T Ganson; Khushi P Patel; Vanessa I Machen; Sara M Buckelew; Andrea K Garber Journal: J Eat Disord Date: 2022-07-18